<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39201826</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">892</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children11080892</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The management of pediatric dermatological conditions such as alopecia areata (AA), psoriasis, atopic dermatitis (AD), and hidradenitis suppurativa (HS) has significantly evolved with the introduction of biologics and small molecule targeted therapies. The advancement in understanding the immunopathogenesis of these chronic skin conditions has led to the development and approval of novel biologics and small molecule therapies. Initially approved by the United States Food and Drug Administration (FDA) for adults, most of these therapies are now being evaluated in clinical trials for safety and efficacy in adolescents and children, expanding new treatment options for pediatric patients. The role of the FDA in drug approval is multifaceted from drug inception, ensuring that research, data, and evidence show that the proposed drug is effective and safe for the intended use.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The goal of this review article is to provide an overview of the recently FDA-approved and potential biologic and oral small molecule therapies in clinical trials for AA, psoriasis, AD, and HS in pediatric patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The search for this review included keywords in ClinicalTrials.gov, PubMed, and Google Scholar for the latest research and clinical trials relevant to these conditions and treatments without the PRISMA methodology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For pediatric AA, ritlecitinib is FDA-approved, while baricitinib and updacitinib are in phase 3 clinical trials for pediatric approval. The FDA-approved drugs for pediatric psoriasis include secukinumab, ustekinumab, ixekizumab, etanercept, and apremilast. Other phase 3 clinical trials for pediatric psoriasis include risankizumab, guselkumab, tildrakizumab, brodalumab, and deucravacitinib. For pediatric AD, the FDA-approved drugs are dupilumab, tralokinumab, abrocitinib, and upadacitinib, with many other drugs in phase 3 trials. Adalimumab is an FDA-approved biologic for pediatric HS, with various clinical trials ongoing for adults. The approved biologics and small molecule therapies had higher efficacy and improved safety profiles compared to traditional medications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">With numerous ongoing trials, the success of these clinical trials could lead to their inclusion in treatment guidelines for these chronic skin conditions. Biologics and small molecule therapies offer new avenues for effective disease management, enabling personalized therapeutic interventions and improving pediatric health outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Robin C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Shannon K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0009-0006-2321-3254</Identifier><AffiliationInfo><Affiliation>Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantz</LastName><ForeName>Hannah Y</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0009-0008-1285-2645</Identifier><AffiliationInfo><Affiliation>Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strowd</LastName><ForeName>Lindsay C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-0090-6289</Identifier><AffiliationInfo><Affiliation>Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Sciences &amp; Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alopecia areata</Keyword><Keyword MajorTopicYN="N">atopic dermatitis</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">drug treatment</Keyword><Keyword MajorTopicYN="N">hidradenitis suppurativa</Keyword><Keyword MajorTopicYN="N">pediatric treatment</Keyword><Keyword MajorTopicYN="N">psoriasis</Keyword><Keyword MajorTopicYN="N">small molecules</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39201826</ArticleId><ArticleId IdType="pmc">PMC11352834</ArticleId><ArticleId IdType="doi">10.3390/children11080892</ArticleId><ArticleId IdType="pii">children11080892</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pratt C.H., King L.E., Jr., Messenger A.G., Christiano A.M., Sundberg J.P. Alopecia areata. Nat. Rev. Dis. Primers. 2017;3:17011. doi: 10.1038/nrdp.2017.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.11</ArticleId><ArticleId IdType="pmc">PMC5573125</ArticleId><ArticleId IdType="pubmed">28300084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E., Lee J.S., Tang M. Current treatment strategies in pediatric alopecia areata. Indian J. Dermatol. 2012;57:459–465. doi: 10.4103/0019-5154.103066.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5154.103066</ArticleId><ArticleId IdType="pmc">PMC3519253</ArticleId><ArticleId IdType="pubmed">23248364</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.W., Kim Y.H., Kwak H., Park J., Lee W.S., Kang H., Kim J.E., Yoon T.Y., Kim K.H., Jang Y.H., et al. Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study. Ann. Dermatol. 2022;34:237–244. doi: 10.5021/ad.21.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.5021/ad.21.202</ArticleId><ArticleId IdType="pmc">PMC9365651</ArticleId><ArticleId IdType="pubmed">35948325</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair H.A. Ritlecitinib: First Approval. Drugs. 2023;83:1315–1321. doi: 10.1007/s40265-023-01928-y. Erratum in Drugs 2023, 83, 1457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01928-y</ArticleId><ArticleId IdType="pmc">PMC10556173</ArticleId><ArticleId IdType="pubmed">37556041</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves Pfizer’s LITFULOTM (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata|Pfizer.  [(accessed on 23 June 2023)].  Available online:  www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and.</Citation></Reference><Reference><Citation>Freitas E., Guttman-Yassky E., Torres T. Baricitinib for the Treatment of Alopecia Areata. Drugs. 2023;83:761–770. doi: 10.1007/s40265-023-01873-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01873-w</ArticleId><ArticleId IdType="pmc">PMC10191081</ArticleId><ArticleId IdType="pubmed">37195491</ArticleId></ArticleIdList></Reference><Reference><Citation>King B., Ohyama M., Kwon O., Zlotogorski A., Ko J., Mesinkovska N.A., Hordinsky M., Dutronc Y., Wu W.S., McCollam J., et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N. Engl. J. Med. 2022;386:1687–1699. doi: 10.1056/NEJMoa2110343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110343</ArticleId><ArticleId IdType="pubmed">35334197</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor P.C., Takeuchi T., Burmester G.R., Durez P., Smolen J.S., Deberdt W., Issa M., Terres J.R., Bello N., Winthrop K.L. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database. Ann. Rheum. Dis. 2022;81:335–343. doi: 10.1136/annrheumdis-2021-221276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221276</ArticleId><ArticleId IdType="pmc">PMC8862028</ArticleId><ArticleId IdType="pubmed">34706874</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of Baricitinib (LY3009104) in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata (BRAVE-AA-PEDS). Clinicaltrials.gov Identifier: NCT05723198. Updated 21 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05723198.</Citation></Reference><Reference><Citation>A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata (Up-AA). Clinicaltrials.gov Identifier: NCT06012240. Updated 3 July 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT06012240.</Citation></Reference><Reference><Citation>Narbutt J., Niedźwiedź M., Lesiak A., Ceryn J., Skibińska M. Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability. Patient Prefer. Adherence. 2023;17:421–431. doi: 10.2147/PPA.S350753.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S350753</ArticleId><ArticleId IdType="pmc">PMC9940655</ArticleId><ArticleId IdType="pubmed">36815128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S.M., Kim W.U. Targeted Immunotherapy for Autoimmune Disease. Immune Netw. 2022;22:e9. doi: 10.4110/in.2022.22.e9.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2022.22.e9</ArticleId><ArticleId IdType="pmc">PMC8901705</ArticleId><ArticleId IdType="pubmed">35291650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodemer C., Kaszuba A., Kingo K., Tsianakas A., Morita A., Rivas E., Papanastasiou P., Keefe D., Patekar M., Charef P., et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J. Eur. Acad. Dermatol. Venereol. 2021;35:938–947. doi: 10.1111/jdv.17002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17002</ArticleId><ArticleId IdType="pmc">PMC7986088</ArticleId><ArticleId IdType="pubmed">33068444</ArticleId></ArticleIdList></Reference><Reference><Citation>Diotallevi F., Simonetti O., Rizzetto G., Molinelli E., Radi G., Offidani A. Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives. Int. J. Mol. Sci. 2022;23:11128. doi: 10.3390/ijms231911128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911128</ArticleId><ArticleId IdType="pmc">PMC9569815</ArticleId><ArticleId IdType="pubmed">36232430</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients with Psoriasis (CADMUS). Clinicaltrials.gov Identifier: NCT01090427. Updated 29 January 2015.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT01090427.</Citation></Reference><Reference><Citation>An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater than or Equal to 6 to Less than 12 Years of Age (CADMUS Jr). Clinicaltrials.gov Identifier: NCT02698475. Updated 1 November 2021.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT02698475.</Citation></Reference><Reference><Citation>Paller A.S., Seyger M.M., Magariños G.A., Pinter A., Cather J.C., Rodriguez-Capriles C., Zhu D., Somani N., Garrelts A., Papp K.A., et al. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients with Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. JAMA Dermatol. 2022;158:533–541. doi: 10.1001/jamadermatol.2022.0655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2022.0655</ArticleId><ArticleId IdType="pmc">PMC9008559</ArticleId><ArticleId IdType="pubmed">35416908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.U., Koo J. Etanercept in the treatment of plaque psoriasis. Clin. Cosmet. Investig. Dermatol. 2009;2:77–84. doi: 10.2147/ccid.s3412.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ccid.s3412</ArticleId><ArticleId IdType="pmc">PMC3047929</ArticleId><ArticleId IdType="pubmed">21436970</ArticleId></ArticleIdList></Reference><Reference><Citation>Paller A.S., Siegfried E.C., Langley R.G., Gottlieb A.B., Pariser D., Landells I., Hebert A.A., Eichenfield L.F., Patel V., Creamer K., et al. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med. 2008;358:241–251. doi: 10.1056/NEJMoa066886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066886</ArticleId><ArticleId IdType="pubmed">18199863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivelevitch D., Mansouri B., Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014;8:169–182. doi: 10.2147/BTT.S41481. doi: 10.2147/btt.s41481.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/BTT.S41481</ArticleId><ArticleId IdType="doi">10.2147/btt.s41481</ArticleId><ArticleId IdType="pmc">PMC4000175</ArticleId><ArticleId IdType="pubmed">24790410</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley E.L., Gooderham M.J. Phosphodiesterase-4 Inhibition in the Management of Psoriasis. Pharmaceutics. 2023;16:23. doi: 10.3390/pharmaceutics16010023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16010023</ArticleId><ArticleId IdType="pmc">PMC10819567</ArticleId><ArticleId IdType="pubmed">38258034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorillo L., Becker E., de Lucas R., Belloni-Fortina A., Maes P., Oberoi R.K., Paris M., Zhang W., Zhang Z., Arkin L. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. J. Am. Acad. Dermatol. 2023;90:1232–1239. doi: 10.1016/j.jaad.2023.11.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2023.11.068</ArticleId><ArticleId IdType="pubmed">38266683</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair H.A. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2020;80:1235–1245. doi: 10.1007/s40265-020-01357-1. Erratum in Drugs 2020, 80, 1505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01357-1</ArticleId><ArticleId IdType="pmc">PMC7475056</ArticleId><ArticleId IdType="pubmed">32632826</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of Subcutaneous Risankizumab Injection for Pediatric Participants with Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1). Clinicaltrials.gov Identifier: NCT04435600. Updated 5 March 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04435600.</Citation></Reference><Reference><Citation>Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years with Moderate to Severe Plaque Psoriasis Treated with Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2). Clinicaltrials.gov Identifier: NCT04862286. Updated 17 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04862286.</Citation></Reference><Reference><Citation>Campbell K., Li K., Yang F., Branigan P., Elloso M.M., Benson J., Orlovsky Y., Chen Y., Garcet S., Krueger J.G. Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. Immunohorizons. 2023;7:273–285. doi: 10.4049/immunohorizons.2300003.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2300003</ArticleId><ArticleId IdType="pmc">PMC10579843</ArticleId><ArticleId IdType="pubmed">37071038</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR). Clinicaltrials.gov Identifier: NCT03451851. Updated 20 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03451851.</Citation></Reference><Reference><Citation>Campione E., Lambiase S., Gaeta Shumak R., Galluzzo M., Lanna C., Costanza G., Borselli C., Artosi F., Cosio T., Tofani L., et al. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals. 2023;16:526. doi: 10.3390/ph16040526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040526</ArticleId><ArticleId IdType="pmc">PMC10141711</ArticleId><ArticleId IdType="pubmed">37111283</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of Tildrakizumab in Pediatric Subjects with Chronic Plaque Psoriasis. Clinicaltrials.gov Identifier: NCT03997786. Updated 21 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03997786.</Citation></Reference><Reference><Citation>Golbari N.M., Basehore B.M., Zito P.M.  StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2024.  [(accessed on 4 July 2024)]. Brodalumab. [Updated 8 August 2023] Available online:  https://www.ncbi.nlm.nih.gov/books/NBK470324/</Citation><ArticleIdList><ArticleId IdType="pubmed">29261896</ArticleId></ArticleIdList></Reference><Reference><Citation>An Open-label, Single-Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects. Clinicaltrials.gov Identifier: NCT03240809. Updated 14 August 2023.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03240809.</Citation></Reference><Reference><Citation>Rusiñol L., Puig L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci. 2023;24:3391. doi: 10.3390/ijms24043391.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043391</ArticleId><ArticleId IdType="pmc">PMC9959504</ArticleId><ArticleId IdType="pubmed">36834806</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants with Moderate to Severe Plaque Psoriasis. Clinicaltrials.gov Identifier: NCT04772079. Updated 9 July 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05478499.</Citation></Reference><Reference><Citation>D’Ippolito D., Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. Pharm. Ther. 2018;43:532–535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110636</ArticleId><ArticleId IdType="pubmed">30186024</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson E.L., Bieber T., Guttman-Yassky E., Beck L.A., Blauvelt A., Cork M.J., Silverberg J.I., Deleuran M., Kataoka Y., Lacour J.P., et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N. Engl. J. Med. 2016;375:2335–2348. doi: 10.1056/NEJMoa1610020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1610020</ArticleId><ArticleId IdType="pubmed">27690741</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to &lt;18 Years with Atopic Dermatitis (Eczema). Clinicaltrials.gov Identifier: NCT02407756. Updated 27 November 2020.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT02407756.</Citation></Reference><Reference><Citation>Santoro C. FDA Approves Tralokinumab for Adolescents with Atopic Dermatitis. AJMC, 18 December 2023.  [(accessed on 4 July 2024)].  Available online:  http://www.ajmc.com/view/fda-approves-tralokinumab-for-adolescents-with-atopic-dermatitis.</Citation></Reference><Reference><Citation>Paller A.S., Flohr C., Cork M., Bewley A., Blauvelt A., Hong H.C.H., Imafuku S., Schuttelaar M.L., Simpson E.L., Soong W., et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis. JAMA Dermatol. 2023;159:596. doi: 10.1001/jamadermatol.2023.0627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2023.0627</ArticleId><ArticleId IdType="pmc">PMC10116386</ArticleId><ArticleId IdType="pubmed">37074705</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks E.D., Duggan S. Abrocitinib: First approval. Drugs. 2021;81:2149–2157. doi: 10.1007/s40265-021-01638-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01638-3</ArticleId><ArticleId IdType="pmc">PMC8917037</ArticleId><ArticleId IdType="pubmed">34807428</ArticleId></ArticleIdList></Reference><Reference><Citation>Study to Evaluate Efficacy and Safety of PF-04965842 with or without Topical Medications in Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis (JADE EXTEND). Clinicaltrials.gov Identifier: NCT03422822. Updated 11 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03422822.</Citation></Reference><Reference><Citation>Padda I.S., Bhatt R., Patel P., Parmar M.  Upadacitinib. StatPearls Publishing; Treasure Island, FL, USA: 2024.  [(accessed on 4 July 2024)].  Available online:  www.ncbi.nlm.nih.gov/books/NBK572088/#:~:text=Mechanism%20of%20Action.</Citation><ArticleIdList><ArticleId IdType="pubmed">34283454</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants with Severe Atopic Dermatitis. Clinicaltrials.gov Identifier: NCT03646604. Updated 17 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT03646604.</Citation></Reference><Reference><Citation>Lé A.M., Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis—Focus on Rocatinlimab and amlitelimab. Pharmaceutics. 2022;14:2753. doi: 10.3390/pharmaceutics14122753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14122753</ArticleId><ArticleId IdType="pmc">PMC9787630</ArticleId><ArticleId IdType="pubmed">36559247</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects with Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO). Clinicaltrials.gov Identifier: NCT05704738. Updated 21 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT05704738.</Citation></Reference><Reference><Citation>A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared with Placebo in Participants Aged 12 Years and Older with Moderate-to-severe Atopic Dermatitis (COAST 2). Clinicaltrials.gov Identifier: NCT06181435. Updated 21 June 2024.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT06181435.</Citation></Reference><Reference><Citation>Safety and Efficacy of Lebrikizumab (LY3650150) in Combination with Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere). Clinicaltrials.gov Identifier: NCT04250337. Updated 9 May 2022.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04250337.</Citation></Reference><Reference><Citation>Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis.Clinicaltrials.gov Identifier: NCT04875169  Updated 1 June 2023.  [(accessed on 4 July 2024)]; Available online:  https://clinicaltrials.gov/study/NCT04875169.</Citation></Reference><Reference><Citation>Ballard K., Shuman V.L.  Hidradenitis Suppurativa. StatPearls Publishing; Treasure Island, FL, USA: 2019.  [(accessed on 4 July 2024)].  Available online:  www.ncbi.nlm.nih.gov/books/NBK534867/</Citation><ArticleIdList><ArticleId IdType="pubmed">30521288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball A.B., Okun M.M., Williams D.A., Gottlieb A.B., Papp K.A., Zouboulis C.C., Armstrong A.W., Kerdel F., Gold M.H., Forman S.B., et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N. Engl. J. Med. 2016;375:422–434. doi: 10.1056/NEJMoa1504370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504370</ArticleId><ArticleId IdType="pubmed">27518661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Y., Liu J., Wang J., Epps R.E., Kettl D., Marcus K., Seo S., Zhu H., Wang Y. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: A Regulatory Perspective. AAPS J. 2019;21:91. doi: 10.1208/s12248-019-0363-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-019-0363-5</ArticleId><ArticleId IdType="pubmed">31325056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball A.B., Jemec G.B.E., Alavi A., Reguiai Z., Gottlieb A.B., Bechara F.G., Paul C., Giamarellos Bourboulis E.J., Villani A.P., Schwinn A., et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401:747–761. doi: 10.1016/S0140-6736(23)00022-3. Erratum in Lancet 2024, 403, 618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00022-3</ArticleId><ArticleId IdType="pubmed">36746171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball A.B., Jemec G.B.E., Sayed C.J., Kirby J.S., Prens E., Ingram J.R., Garg A., Gottlieb A.B., Szepietowski J.C., Bechara F.G., et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403:2504–2519. doi: 10.1016/S0140-6736(24)00101-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00101-6</ArticleId><ArticleId IdType="pubmed">38795716</ArticleId></ArticleIdList></Reference><Reference><Citation>Martora F., Scalvenzi M., Ruggiero A., Potestio L., Battista T., Megna M. Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina. 2023;59:801. doi: 10.3390/medicina59040801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina59040801</ArticleId><ArticleId IdType="pmc">PMC10146646</ArticleId><ArticleId IdType="pubmed">37109759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanatoula D.D., Bodner E., Ghoreschi K., Meier K., Solimani F. Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases. JDDG J. Der Dtsch. Dermatol. Ges. 2024;22:400–421. doi: 10.1111/ddg.15270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.15270</ArticleId><ArticleId IdType="pubmed">38259085</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton V.R., Toussi A., Awasthi S., Kiuru M. Treatment of pediatric alopecia areata: A systematic review. J. Am. Acad. Dermatol. 2022;86:1318–1334. doi: 10.1016/j.jaad.2021.04.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.04.077</ArticleId><ArticleId IdType="pmc">PMC8556406</ArticleId><ArticleId IdType="pubmed">33940103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai V.W.Y., Chen G., Gin D., Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J. Am. Acad. Dermatol. 2019;81:694–701. doi: 10.1016/j.jaad.2019.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2019.04.053</ArticleId><ArticleId IdType="pubmed">31048013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando T., Goldman R.D. Corticosteroids for alopecia areata in children. Can. Fam. Physician. 2020;66:499–501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365156</ArticleId><ArticleId IdType="pubmed">32675094</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronckers I.M., Paller A.S., West D.P., Lara-Corrales I., Tollefson M.M., Tom W.L., Hogeling M., Belazarian L., Zachariae C., Mahé E., et al. A Comparison of Psoriasis Severity in Pediatric Patients Treated with Methotrexate vs. Biologic Agents. JAMA Dermatol. 2020;156:384–392. doi: 10.1001/jamadermatol.2019.4835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2019.4835</ArticleId><ArticleId IdType="pmc">PMC7042803</ArticleId><ArticleId IdType="pubmed">32022846</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano M., Megna M., Balato A., Ayala F., Lembo S., Villani A., Balato N. Systemic Treatment of Pediatric Psoriasis: A Review. Dermatol. Ther. 2016;6:125–142. doi: 10.1007/s13555-016-0117-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-016-0117-6</ArticleId><ArticleId IdType="pmc">PMC4906111</ArticleId><ArticleId IdType="pubmed">27085539</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxweiler W.T., Agans R., Morrell D.S. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr. Dermatol. 2011;28:689–694. doi: 10.1111/j.1525-1470.2011.01488.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1470.2011.01488.x</ArticleId><ArticleId IdType="pubmed">21967657</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller M., Shin H.T., Orlow S.J., Schaffer J.V. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. Br. J. Dermatol. 2007;157:127–132. doi: 10.1111/j.1365-2133.2007.07947.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.07947.x</ArticleId><ArticleId IdType="pubmed">17489974</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinelli E., De Simoni E., Candelora M., Sapigni C., Brisigotti V., Rizzetto G., Offidani A., Simonetti O. Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues. Antibiotics. 2023;12:978. doi: 10.3390/antibiotics12060978.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12060978</ArticleId><ArticleId IdType="pmc">PMC10295086</ArticleId><ArticleId IdType="pubmed">37370297</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson M.D., Zauli S., Bettoli V., Boer J., Jemec G.B. Cyclosporine treatment of severe Hidradenitis suppurativa—A case series. J. Dermatolog. Treat. 2016;27:247–250. doi: 10.3109/09546634.2015.1088128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09546634.2015.1088128</ArticleId><ArticleId IdType="pubmed">26406923</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson R., Ma E., Parvathala N., Shih T., Atluri S., Hogeling M., Hughes M., Sayed C.J., Shi V.Y., Hsiao J.L. Efficacy of Medical Treatments for Pediatric Hidradenitis Suppurativa: A Systematic Review. Pediatr. Dermatol. 2023;40:775–788. doi: 10.1111/pde.15404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.15404</ArticleId><ArticleId IdType="pubmed">37525978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemec G.B. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin. Exp. Dermatol. 2002;27:528–529. doi: 10.1046/j.1365-2230.2002.11125.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2230.2002.11125.x</ArticleId><ArticleId IdType="pubmed">12372104</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton C.H., Chen S.X., Hussain S.H., Lara-Corrales I., Zaenglein A.L. Hidradenitis Suppurativa in Pediatric Patients. Pediatrics. 2023;151:e2022061049. doi: 10.1542/peds.2022-061049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-061049</ArticleId><ArticleId IdType="pubmed">37102307</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>